HUTCHMED Enters $1.3B Deal With GSK for Ex-China Rights to Preclinical Cancer Therapy HMPL-A830
HUTCHMED has entered a co-development and licensing agreement with GlaxoSmithKline (GSK) worth up to approximately $1.3 billion for ex-China rights to its preclinical therapy, HMPL-A830. The deal includes an upfront payment of $110 million and potential tiered royalties if the drug is commercialized. HMPL-A830 is a KRAS-EGFR antibody-targeted therapy conjugate (ATTC) designed to target EGFR-overexpressing tumor cells while delivering a KRAS payload. This dual approach aims to address resistance mechanisms in cancers such as colorectal, pancreatic, and lung tumors that often overexpress EGFR. HUTCHMED will lead the global Phase I development of HMPL-A830 before GSK takes responsibility for further development outside China. The partnership aligns with HUTCHMED's strategy to build a globally competitive oncology portfolio through innovation and strategic collaborations.
Topics: biotech partnership GSK collaboration KRAS-EGFR therapy